Obermatt

Smith & Nephew

LSE:SN. · GB0009223206
Health Care Equipment & SuppliesX-Large

360

86
EV / EBIT73
Price / Owner Earnings51
Owner Earnings Yield67
Dividend Yield76
Price/Sales47
EV / Gross Profit79
Price/Book51
Return on Capital43
Cash Return on Capital57
Return on Equity65
EBIT Margin45
Gross Profitability62
Cash Conversion72
Accruals73
Owner Earnings Margin61
Sales growth66
Profit Growth83
Long-Term EPS Growth51
Owner Earnings Growth71
Reinvestment62
Price momentum70
Debt load39
Refinancing75
Debt Payback29
Liquidity48
Analyst ratings27
Opinion Changes55
Price Target Upside50
Market mood50
Value Creation12/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Smith & Nephew clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Profile

CountryUK
IndustryHealth Care Equipment & Supplies
SizeX-Large
TypePublic Company
ExchangeLSE
Founded1937
Employees13,640
ISINGB0009223206
Last UpdateApr 2, 2026
Themes
Health DiagnosticsChronic DiseasesArtificial IntelligenceBiomedical EngineeringEar Nose & Throat (ENT)OrthopaedicsSurgeryBiotechnologyHealth CareScience and Engineering

Description

Smith & Nephew plc (SmithNephew) develops, manufactures, markets and sells medical devices and services. The company is working to improve the quality of healthcare through the company’s investment in new technologies and services, clinical evidence…

Analysis

Middle-of-the-road

Smith & Nephew plc is a middle-of-the-road business: neither the economics nor the price stand out from the peer group.

The price is fair. You pay 19.0× its owner earnings: the cash an owner could take out each year, which is in the historically fair zone. At today's price, the market is assuming roughly 6% yearly growth; analysts expect 11%. The price, in other words, assumes less than the experts do.

The trajectory is moderate and the balance sheet is adequate. The company scores 12/20 on our value-creation score: creating some value. Analysts lean positive.

Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
94
2023202420252026

All-time high

98

Jan 2026

All-time low

23

Jan 2023

Average rank

79

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
47
62
62
68
Price/Earnings
63
89
84
84
Price/Book
51
63
66
74
Dividend Yield
76
88
84
82
Value (overall)
62
78
79
89

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Smith & Nephew with its peers
Straumann
VTX:STMN
40
CountrySwitzerland
IndustryHealth Care Equipment & Supplies
SizeLarge
Full Stock Analysis →
Medacta Group
SWX:MOVE
33
CountrySwitzerland
IndustryHealth Care Equipment & Supplies
SizeMedium
Full Stock Analysis →
medmix
SWX:MEDX
54
CountrySwitzerland
IndustryHealth Care Equipment & Supplies
SizeSmall
Full Stock Analysis →
Medartis Holding
SWX:MED
33
CountrySwitzerland
IndustryHealth Care Equipment & Supplies
SizeSmall
Full Stock Analysis →
Medtronic
NYQ:MDT
70
CountryIreland
IndustryHealth Care Equipment & Supplies
SizeXX-Large
Full Stock Analysis →
Carl Zeiss Meditec
GER:AFX
50
CountryGermany
IndustryHealth Care Equipment & Supplies
SizeLarge
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →